Search

Your search keyword '"Harrington, Kevin J"' showing total 1,244 results
Start Over Author "Harrington, Kevin J"
1,244 results on '"Harrington, Kevin J"'

1. Sculpting the tumour microenvironment by combining radiotherapy and ATR inhibition for curative-intent adjuvant immunotherapy

Author

Patin, Emmanuel C., Nenclares, Pablo, Chan Wah Hak, Charleen, Dillon, Magnus T., Patrikeev, Anton, McLaughlin, Martin, Grove, Lorna, Foo, Shane, Soliman, Heba, Barata, Joao P., Marsden, Joanna, Baldock, Holly, Gkantalis, Jim, Roulstone, Victoria, Kyula, Joan, Burley, Amy, Hubbard, Lisa, Pedersen, Malin, Smith, Simon A., Clancy-Thompson, Eleanor, Melcher, Alan A., Ono, Masahiro, Rullan, Antonio, and Harrington, Kevin J.

Published
2024
Full Text
View/download PDF

5. Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial

Author

Rischin, Danny, Hughes, Brett GM, Gao, Bo, McGrath, Margaret, Greil, Richard, Thurnher, Dietmar, Fuereder, Thorsten, Burian, Martin, Rottey, Sylvie, Machiels, Jean-Pascal, Clement, Paul M, Henry, Stéphanie, Deheneffe, Stéphanie, Vasconcelos Alves, Gustavo, Lima, Iane Pinto Figueiredo, Mourão Dias, Josiane, De Marchi, Pedro Rafael Martins, Mak, Milena Perez, Pereira de Santana Gomes, Andrea Juliana, Oliveira de Castro Junior, Dalvaro, Motta, Tatiane Cardoso, Agostinho Padoan, Monica Luciana, Victorina, Ana Paula, de Azevedo, Sergio Jobim, Siu, Lillian L, Brule, Stephanie, Hilton, John, Wang, Chang Shu, Bouganim, Nathaniel, Webster, Marc, Walker, John, Chua, Neil, Zambrano, Angela Regina, Quiroga Echeverri, Alicia, Niño Gomez, Oscar Mauricio, Ortiz, Carlos Alberto, Rojas, Luis, Cardona Zorilla, Andrés, Urrego Meléndez, Olga Marcela, Holečková, Petra Beran, Melichar, Bohuslav, Cvek, Jakub, Prausová, Jana, Vošmik, Milan, Delord, Jean-Pierre, Zasadny, Xavier, Geoffrois, Lionnel, Tao, Yungan, Pointreau, Yoann, Fietkau, Rainer, Haderlein, Marlen, Mueller, Andreas H, Schroeder, Ursula, Wollenberg, Barbara, Laban, Simon, Ivanyi, Philipp, Gruenwald, Viktor, Schafhausen, Philippe, Gutfeld, Orit, Gluck, Iris, Popovtzer, Aron, Meirovitz, Amichay, Billan, Salem, Brenner, Baruch, Limon, Dror, Licitra, Lisa, Perri, Francesco, Caponigro, Francesco, Violati, Martina, Ferrari, Daris, Nole, Franco, Bertolini, Federica, Livi, Lorenzo, Ghi, Maria Grazia, Imarisio, Ilaria, Tahara, Makoto, Homma, Akihiro, Ueda, Tsutomu, Asada, Yukinori, Yamazaki, Tomoko, Matsumoto, Koji, Fujii, Takashi, Ikeda, Sadakatsu, Takahashi, Shunji, Kinoshita, Takashi, Sasaki, Keita, Tsuji, Akihito, Ahn, Myung-Ju, Cho, Byoung Chul, Lee, Keun-Wook, Lee, Ki Hyeong, Choi, Moon Ki, Yun, Hwan Jung, Hendriks, Mathijs P, Oosting, Sjoukje F, Buter, Jan, Van Meerten, Esther, Graham, Jonathan, Kawecki, Andrzej, Debicka, Izabella, Maciejczyk, Adam, Pysz, Maciej, Filarska, Dorota, Hetnał, Marcin, Koralewski, Piotr, Wygoda, Andrzej, Składowski, Krzysztof, Talerczyk, Małgorzata, Berrocal Jaime, Alfonso, Pérez Segura, Pedro, Braña García, Irene, Basté Rotllan, Neus, Mesía Nin, Ricard, Taberna Sanz, Miren, Iglesias Docampo, Lara, Soria Rivas, Ainara, Rueda Domínguez, Antonio, Trigo Pérez, José Manuel, Hong, Ruey-Long, Li, Shau-Hsuan, Wang, Hung-Ming, Yen, Chia-Jui, Yang, Muh-Hwa, Chang, Yi-Fang, Liu, Yi-Chun, Lin, Jin-Ching, Ekenel, Meltem, Harputluoğlu, Hakan, Aksoy, Sercan, Özyilkan, Özgür, Bılıcı, Ahmet, Şendur, Mehmet Alı Nahıt, Arslan, Cagatay, Harrington, Kevin, Ramkumar, Shanmugasundaram, Gujral, Dorothy, Stewart, Simon, Powell, Melanie, Sibtain, Amen, Roques, Tom, Yip, Kent, Mirza, Arafat, Sivaramalingam, Muthiah, Belman, Neil D, Agarwala, Sanjiv, Anderson, Ian, Patel, Arpan, Maggiore, Ronald, Baumgart, Megan, Burtness, Barbara, Fidler, Mary Jo, Kaur, Varinder, Gaughan, Elizabeth, Worden, Francis, Rodriguez, Cristina P, Sukari, Ammar, Wong, Deborah, Yom, Sue, Walsh, William V, Fiorillo, Joseph A, Yorio, Jeffrey T, Obara, Grzegorz S, Alves, Gustavo, Hughes, Brett G M, Mesía, Ricard, Taberna, Miren, Waldron, John N, Simon, Christian, Grégoire, Vincent, Harrington, Kevin J, Swaby, Ramona F, Zhang, Yayan, Gumuscu, Burak, and Bidadi, Behzad

Published
2024
Full Text
View/download PDF

7. Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation

Author

Dillon, Magnus T., Guevara, Jeane, Mohammed, Kabir, Patin, Emmanuel C., Smith, Simon A., Dean, Emma, Jones, Gemma N., Willis, Sophie E., Petrone, Marcella, Silva, Carlos, Thway, Khin, Bunce, Catey, Roxanis, Ioannis, Nenclares, Pablo, Wilkins, Anna, McLaughlin, Martin, Jayme-Laiche, Adoracion, Benafif, Sarah, Nintos, Georgios, Kwatra, Vineet, Grove, Lorna, Mansfield, David, Proszek, Paula, Martin, Philip, Moore, Luiza, Swales, Karen E., Banerji, Udai, Saunders, Mark P., Spicer, James, Forster, Martin D., and Harrington, Kevin J.

Subjects
Tumors -- Drug therapy -- Genetic aspects, Inflammation -- Drug therapy -- Genetic aspects, Health care industry
Abstract

BACKGROUND. Phase 1 study of ATR inhibition alone or with radiation therapy (PATRIOT) was a first-in-human phase I study of the oral ATR (ataxia telangiectasia and Rad3-related) inhibitor ceralasertib (AZD6738) in advanced solid tumors. METHODS. The primary objective was safety. Secondary objectives included assessment of antitumor responses and pharmacokinetic (PK) and pharmacodynamic (PD) studies. Sixty-seven patients received 20-240 mg ceralasertib BD continuously or intermittently (14 of a 28-day cycle). RESULTS. Intermittent dosing was better tolerated than continuous, which was associated with dose-limiting hematological toxicity. The recommended phase 2 dose of ceralasertib was 160 mg twice daily for 2 weeks in a 4-weekly cycle. Modulation of target and increased DNA damage were identified in tumor and surrogate PD. There were 5 (8%) confirmed partial responses (PRs) (40-240 mg BD), 34 (52%) stable disease (SD), including 1 unconfirmed PR, and 27 (41%) progressive disease. Durable responses were seen in tumors with loss of AT-rich interactive domain-containing protein 1A (ARID1A) and DNA damageresponse defects. Treatment-modulated tumor and systemic immune markers and responding tumors were more immune inflamed than nonresponding. CONCLUSION. Ceralasertib monotherapy was tolerated at 160 mg BD intermittently and associated with antitumor activity. TRIAL REGISTRATION. Clinicaltrials.gov: NCT02223923, EudraCT: 2013-003994-84. FUNDING. Cancer Research UK, AstraZeneca, UK Department of Health (National Institute for Health Research), Rosetrees Trust, Experimental Cancer Medicine Centre., Introduction ATR (ataxia telangiectasia and Rad3-related) is a critical kinase in the DNA damage response (DDR) (1, 2). Preclinical data have identified multiple cancer-related phenotypes sensitizing tumor cells to monotherapy [...]

Published
2024
Full Text
View/download PDF

10. Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040.

Author

Harrington, Kevin J, Soulières, Denis, Le Tourneau, Christophe, Dinis, Jose, Licitra, Lisa F, Ahn, Myung-Ju, Soria, Ainara, Machiels, Jean-Pascal H, Mach, Nicolas, Mehra, Ranee, Burtness, Barbara, Ellison, Misoo C, Cheng, Jonathan D, Chirovsky, Diana Romana, Swaby, Ramona F, and Cohen, Ezra EW

Subjects
Clinical Research, Rare Diseases, Cancer, Dental/Oral and Craniofacial Disease, Good Health and Well Being, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Cetuximab, Disease-Free Survival, Docetaxel, Humans, Male, Middle Aged, Neoplasm Metastasis, Neoplasm Recurrence, Local, Patient Reported Outcome Measures, Quality of Life, Squamous Cell Carcinoma of Head and Neck, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

BackgroundHead and neck squamous cell carcinoma (HNSCC) affects health-related quality of life (HRQoL); few treatments have demonstrated clinically meaningful HRQoL benefit. KEYNOTE-040 evaluated pembrolizumab vs standard of care (SOC) in patients with recurrent and/or metastatic HNSCC whose disease recurred or progressed after platinum-containing regimen.MethodsPatients received pembrolizumab 200 mg or SOC (methotrexate, docetaxel, or cetuximab). Exploratory HRQoL analyses used European Organisation for Research and Treatment of Cancer (EORTC) 30 quality-of-life, EORTC 35-question quality-of-life head and neck cancer-specific module, and EuroQoL 5-dimensions questionnaires.ResultsThe HRQoL population comprised 469 patients (pembrolizumab = 241, SOC = 228). HRQoL compliance for patients in the study at week 15 was 75.3% (116 of 154) for pembrolizumab and 74.6% (85 of 114) for SOC. The median time to deterioration in global health status (GHS) and QoL scores were 4.8 months with pembrolizumab and 2.8 months with SOC (hazard ratio = 0.79, 95% confidence interval [CI] = 0.59 to 1.05). At week 15, GHS / QoL scores were stable for pembrolizumab (least squares mean [LSM] = 0.39, 95% CI = -3.00 to 3.78) but worsened for SOC (LSM = -5.86, 95% CI = -9.68 to -2.04); the LSM between-group difference was 6.25 points (95% CI = 1.32 to 11.18; nominal 2-sided P = .01). A greater difference in the LSM for GHS / QoL score occurred with pembrolizumab vs docetaxel (10.23, 95% CI = 3.15 to 17.30) compared with pembrolizumab vs methotrexate (6.21, 95% CI = -4.57 to 16.99) or pembrolizumab vs cetuximab (-1.44, 95% CI = -11.43 to 8.56). Pembrolizumab-treated patients had stable functioning and symptoms at week 15, with no notable differences from SOC.ConclusionsGHS / QoL scores were stable with pembrolizumab but declined with SOC in patients at week 15, supporting the clinically meaningful benefit of pembrolizumab in recurrent and/or metastatic HNSCC.

Published
2021

11. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death

Author

Galluzzi, Lorenzo, Vitale, Ilio, Warren, Sarah, Adjemian, Sandy, Agostinis, Patrizia, Martinez, Aitziber Buqué, Chan, Timothy A, Coukos, George, Demaria, Sandra, Deutsch, Eric, Draganov, Dobrin, Edelson, Richard L, Formenti, Silvia C, Fucikova, Jitka, Gabriele, Lucia, Gaipl, Udo S, Gameiro, Sofia R, Garg, Abhishek D, Golden, Encouse, Han, Jian, Harrington, Kevin J, Hemminki, Akseli, Hodge, James W, Hossain, Dewan Md Sakib, Illidge, Tim, Karin, Michael, Kaufman, Howard L, Kepp, Oliver, Kroemer, Guido, Lasarte, Juan Jose, Loi, Sherene, Lotze, Michael T, Manic, Gwenola, Merghoub, Taha, Melcher, Alan A, Mossman, Karen L, Prosper, Felipe, Rekdal, Øystein, Rescigno, Maria, Riganti, Chiara, Sistigu, Antonella, Smyth, Mark J, Spisek, Radek, Stagg, John, Strauss, Bryan E, Tang, Daolin, Tatsuno, Kazuki, van Gool, Stefaan W, Vandenabeele, Peter, Yamazaki, Takahiro, Zamarin, Dmitriy, Zitvogel, Laurence, Cesano, Alessandra, and Marincola, Francesco M

Subjects
Inflammatory and immune system, Consensus, Guidelines as Topic, Humans, Immunogenic Cell Death, Molecular Biology, oncology, immunology, molecular biology
Abstract

Cells succumbing to stress via regulated cell death (RCD) can initiate an adaptive immune response associated with immunological memory, provided they display sufficient antigenicity and adjuvanticity. Moreover, multiple intracellular and microenvironmental features determine the propensity of RCD to drive adaptive immunity. Here, we provide an updated operational definition of immunogenic cell death (ICD), discuss the key factors that dictate the ability of dying cells to drive an adaptive immune response, summarize experimental assays that are currently available for the assessment of ICD in vitro and in vivo, and formulate guidelines for their interpretation.

Published
2020

12. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)

Author

Cohen, Ezra EW, Bell, R Bryan, Bifulco, Carlo B, Burtness, Barbara, Gillison, Maura L, Harrington, Kevin J, Le, Quynh-Thu, Lee, Nancy Y, Leidner, Rom, Lewis, Rebecca L, Licitra, Lisa, Mehanna, Hisham, Mell, Loren K, Raben, Adam, Sikora, Andrew G, Uppaluri, Ravindra, Whitworth, Fernanda, Zandberg, Dan P, and Ferris, Robert L

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Immunology, Vaccine Related, Immunization, Cancer, Clinical Research, Dental/Oral and Craniofacial Disease, Rare Diseases, Orphan Drug, Development of treatments and therapeutic interventions, 5.1 Pharmaceuticals, Good Health and Well Being, B7-H1 Antigen, Consensus, Drug Approval, Head and Neck Neoplasms, Humans, Immunotherapy, Patient Selection, Practice Guidelines as Topic, Societies, Medical, Squamous Cell Carcinoma of Head and Neck, United States, United States Food and Drug Administration, Guidelines, Head and neck cancer, Head and neck squamous cell carcinoma, Immune checkpoint inhibitor, Oncology and carcinogenesis
Abstract

Head and neck cancers, including those of the lip and oral cavity, nasal cavity, paranasal sinuses, oropharynx, larynx and nasopharynx represent nearly 700,000 new cases and 380,000 deaths worldwide per annum, and account for over 10,000 annual deaths in the United States alone. Improvement in outcomes are needed for patients with recurrent and or metastatic squamous cell carcinoma of the head and neck (HNSCC). In 2016, the US Food and Drug Administration (FDA) granted the first immunotherapeutic approvals - the anti-PD-1 immune checkpoint inhibitors nivolumab and pembrolizumab - for the treatment of patients with recurrent squamous cell carcinoma of the head and neck (HNSCC) that is refractory to platinum-based regimens. The European Commission followed in 2017 with approval of nivolumab for treatment of the same patient population, and shortly thereafter with approval of pembrolizumab monotherapy for the treatment of recurrent or metastatic HNSCC in adults whose tumors express PD-L1 with a ≥ 50% tumor proportion score and have progressed on or after platinum-containing chemotherapy. Then in 2019, the FDA granted approval for PD-1 inhibition as first-line treatment for patients with metastatic or unresectable, recurrent HNSCC, approving pembrolizumab in combination with platinum and fluorouracil for all patients with HNSCC and pembrolizumab as a single agent for patients with HNSCC whose tumors express a PD-L1 combined positive score ≥ 1. These approvals marked the first new therapies for these patients since 2006, as well as the first immunotherapeutic approvals in this disease. In light of the introduction of these novel therapies for the treatment of patients with head and neck cancer, The Society for Immunotherapy of Cancer (SITC) formed an expert committee tasked with generating consensus recommendations for emerging immunotherapies, including appropriate patient selection, therapy sequence, response monitoring, adverse event management, and biomarker testing. These consensus guidelines serve as a foundation to assist clinicians' understanding of the role of immunotherapies in this disease setting, and to standardize utilization across the field for patient benefit. Due to country-specific variances in approvals, availability and regulations regarding the discussed agents, this panel focused solely on FDA-approved drugs for the treatment of patients in the U.S.

Published
2019

13. Figure 5 from FUME-TCRseq Enables Sensitive and Accurate Sequencing of the T-cell Receptor from Limited Input of Degraded RNA

Author

Baker, Ann-Marie, primary, Nageswaran, Gayathri, primary, Nenclares, Pablo, primary, Ronel, Tahel, primary, Smith, Kane, primary, Kimberley, Christopher, primary, Laclé, Miangela M., primary, Bhide, Shreerang, primary, Harrington, Kevin J., primary, Melcher, Alan, primary, Rodriguez-Justo, Manuel, primary, Chain, Benny, primary, and Graham, Trevor A., primary

Published
2024
Full Text
View/download PDF

14. Figure 6 from FUME-TCRseq Enables Sensitive and Accurate Sequencing of the T-cell Receptor from Limited Input of Degraded RNA

Author

Baker, Ann-Marie, primary, Nageswaran, Gayathri, primary, Nenclares, Pablo, primary, Ronel, Tahel, primary, Smith, Kane, primary, Kimberley, Christopher, primary, Laclé, Miangela M., primary, Bhide, Shreerang, primary, Harrington, Kevin J., primary, Melcher, Alan, primary, Rodriguez-Justo, Manuel, primary, Chain, Benny, primary, and Graham, Trevor A., primary

Published
2024
Full Text
View/download PDF

15. Supplementary Data from FUME-TCRseq Enables Sensitive and Accurate Sequencing of the T-cell Receptor from Limited Input of Degraded RNA

Author

Baker, Ann-Marie, primary, Nageswaran, Gayathri, primary, Nenclares, Pablo, primary, Ronel, Tahel, primary, Smith, Kane, primary, Kimberley, Christopher, primary, Laclé, Miangela M., primary, Bhide, Shreerang, primary, Harrington, Kevin J., primary, Melcher, Alan, primary, Rodriguez-Justo, Manuel, primary, Chain, Benny, primary, and Graham, Trevor A., primary

Published
2024
Full Text
View/download PDF

16. Figure 1 from FUME-TCRseq Enables Sensitive and Accurate Sequencing of the T-cell Receptor from Limited Input of Degraded RNA

Author

Baker, Ann-Marie, primary, Nageswaran, Gayathri, primary, Nenclares, Pablo, primary, Ronel, Tahel, primary, Smith, Kane, primary, Kimberley, Christopher, primary, Laclé, Miangela M., primary, Bhide, Shreerang, primary, Harrington, Kevin J., primary, Melcher, Alan, primary, Rodriguez-Justo, Manuel, primary, Chain, Benny, primary, and Graham, Trevor A., primary

Published
2024
Full Text
View/download PDF

17. Data from FUME-TCRseq Enables Sensitive and Accurate Sequencing of the T-cell Receptor from Limited Input of Degraded RNA

Author

Baker, Ann-Marie, primary, Nageswaran, Gayathri, primary, Nenclares, Pablo, primary, Ronel, Tahel, primary, Smith, Kane, primary, Kimberley, Christopher, primary, Laclé, Miangela M., primary, Bhide, Shreerang, primary, Harrington, Kevin J., primary, Melcher, Alan, primary, Rodriguez-Justo, Manuel, primary, Chain, Benny, primary, and Graham, Trevor A., primary

Published
2024
Full Text
View/download PDF

18. Figure 3 from FUME-TCRseq Enables Sensitive and Accurate Sequencing of the T-cell Receptor from Limited Input of Degraded RNA

Author

Baker, Ann-Marie, primary, Nageswaran, Gayathri, primary, Nenclares, Pablo, primary, Ronel, Tahel, primary, Smith, Kane, primary, Kimberley, Christopher, primary, Laclé, Miangela M., primary, Bhide, Shreerang, primary, Harrington, Kevin J., primary, Melcher, Alan, primary, Rodriguez-Justo, Manuel, primary, Chain, Benny, primary, and Graham, Trevor A., primary

Published
2024
Full Text
View/download PDF

19. Figure 4 from FUME-TCRseq Enables Sensitive and Accurate Sequencing of the T-cell Receptor from Limited Input of Degraded RNA

Author

Baker, Ann-Marie, primary, Nageswaran, Gayathri, primary, Nenclares, Pablo, primary, Ronel, Tahel, primary, Smith, Kane, primary, Kimberley, Christopher, primary, Laclé, Miangela M., primary, Bhide, Shreerang, primary, Harrington, Kevin J., primary, Melcher, Alan, primary, Rodriguez-Justo, Manuel, primary, Chain, Benny, primary, and Graham, Trevor A., primary

Published
2024
Full Text
View/download PDF

20. Figure 2 from FUME-TCRseq Enables Sensitive and Accurate Sequencing of the T-cell Receptor from Limited Input of Degraded RNA

Author

Baker, Ann-Marie, primary, Nageswaran, Gayathri, primary, Nenclares, Pablo, primary, Ronel, Tahel, primary, Smith, Kane, primary, Kimberley, Christopher, primary, Laclé, Miangela M., primary, Bhide, Shreerang, primary, Harrington, Kevin J., primary, Melcher, Alan, primary, Rodriguez-Justo, Manuel, primary, Chain, Benny, primary, and Graham, Trevor A., primary

Published
2024
Full Text
View/download PDF

21. Combination of oncolytic Maraba virus with immune checkpoint blockade overcomes therapy resistance in an immunologically cold model of advanced melanoma with dysfunctional T cell receptor signalling.

Author

Armstrong, Edward, primary, Chiu, Matthew K.L., additional, Foo, Shane, additional, Appleton, Lizzie, additional, Nenclares, Pablo, additional, Patrikeev, Anton, additional, Mohan, Niyta, additional, McLaughlin, Martin, additional, Bozhanova, Galabina, additional, Hoebart, Julia, additional, Roulstone, Victoria, additional, Patin, Emmanuel Christian, additional, Pedersen, Malin, additional, Kyula, Joan, additional, Errington-Mais, Fiona, additional, Bell, John C, additional, Harrington, Kevin J, additional, Melcher, Alan A, additional, and Jennings, Victoria A, additional

Published
2024
Full Text
View/download PDF

23. Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048

Author

Rischin, Danny, Harrington, Kevin J., Greil, Richard, Soulières, Denis, Tahara, Makoto, de Castro Jr, Gilberto, Psyrri, Amanda, Braña, Irene, Neupane, Prakash, Bratland, Åse, Fuereder, Thorsten, Hughes, Brett G.M., Mesía, Ricard, Ngamphaiboon, Nuttapong, Rordorf, Tamara, Ishak, Wan Zamaniah Wan, Hong, Ruey-Long, Mendoza, René Gonzalez, Jia, Liyi, Chirovsky, Diana, Norquist, Josephine, Jin, Fan, and Burtness, Barbara

Published
2022
Full Text
View/download PDF

27. Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial

Author

Machiels, Jean-Pascal, primary, Tao, Yungan, additional, Licitra, Lisa, additional, Burtness, Barbara, additional, Tahara, Makoto, additional, Rischin, Danny, additional, Alves, Gustavo, additional, Lima, Iane Pinto Figueiredo, additional, Hughes, Brett G M, additional, Pointreau, Yoann, additional, Aksoy, Sercan, additional, Laban, Simon, additional, Greil, Richard, additional, Burian, Martin, additional, Hetnał, Marcin, additional, Delord, Jean-Pierre, additional, Mesía, Ricard, additional, Taberna, Miren, additional, Waldron, John N, additional, Simon, Christian, additional, Grégoire, Vincent, additional, Harrington, Kevin J, additional, Swaby, Ramona F, additional, Zhang, Yayan, additional, Gumuscu, Burak, additional, Bidadi, Behzad, additional, Siu, Lillian L, additional, Hughes, Brett GM, additional, Gao, Bo, additional, McGrath, Margaret, additional, Thurnher, Dietmar, additional, Fuereder, Thorsten, additional, Rottey, Sylvie, additional, Machiels, Jean-Pascal, additional, Clement, Paul M, additional, Henry, Stéphanie, additional, Deheneffe, Stéphanie, additional, Vasconcelos Alves, Gustavo, additional, Mourão Dias, Josiane, additional, De Marchi, Pedro Rafael Martins, additional, Mak, Milena Perez, additional, Pereira de Santana Gomes, Andrea Juliana, additional, Oliveira de Castro Junior, Dalvaro, additional, Motta, Tatiane Cardoso, additional, Agostinho Padoan, Monica Luciana, additional, Victorina, Ana Paula, additional, de Azevedo, Sergio Jobim, additional, Brule, Stephanie, additional, Hilton, John, additional, Wang, Chang Shu, additional, Bouganim, Nathaniel, additional, Webster, Marc, additional, Walker, John, additional, Chua, Neil, additional, Zambrano, Angela Regina, additional, Quiroga Echeverri, Alicia, additional, Niño Gomez, Oscar Mauricio, additional, Ortiz, Carlos Alberto, additional, Rojas, Luis, additional, Cardona Zorilla, Andrés, additional, Urrego Meléndez, Olga Marcela, additional, Holečková, Petra Beran, additional, Melichar, Bohuslav, additional, Cvek, Jakub, additional, Prausová, Jana, additional, Vošmik, Milan, additional, Zasadny, Xavier, additional, Geoffrois, Lionnel, additional, Fietkau, Rainer, additional, Haderlein, Marlen, additional, Mueller, Andreas H, additional, Schroeder, Ursula, additional, Wollenberg, Barbara, additional, Ivanyi, Philipp, additional, Gruenwald, Viktor, additional, Schafhausen, Philippe, additional, Gutfeld, Orit, additional, Gluck, Iris, additional, Popovtzer, Aron, additional, Meirovitz, Amichay, additional, Billan, Salem, additional, Brenner, Baruch, additional, Limon, Dror, additional, Perri, Francesco, additional, Caponigro, Francesco, additional, Violati, Martina, additional, Ferrari, Daris, additional, Nole, Franco, additional, Bertolini, Federica, additional, Livi, Lorenzo, additional, Ghi, Maria Grazia, additional, Imarisio, Ilaria, additional, Homma, Akihiro, additional, Ueda, Tsutomu, additional, Asada, Yukinori, additional, Yamazaki, Tomoko, additional, Matsumoto, Koji, additional, Fujii, Takashi, additional, Ikeda, Sadakatsu, additional, Takahashi, Shunji, additional, Kinoshita, Takashi, additional, Sasaki, Keita, additional, Tsuji, Akihito, additional, Ahn, Myung-Ju, additional, Cho, Byoung Chul, additional, Lee, Keun-Wook, additional, Lee, Ki Hyeong, additional, Choi, Moon Ki, additional, Yun, Hwan Jung, additional, Hendriks, Mathijs P, additional, Oosting, Sjoukje F, additional, Buter, Jan, additional, Van Meerten, Esther, additional, Graham, Jonathan, additional, Kawecki, Andrzej, additional, Debicka, Izabella, additional, Maciejczyk, Adam, additional, Pysz, Maciej, additional, Filarska, Dorota, additional, Koralewski, Piotr, additional, Wygoda, Andrzej, additional, Składowski, Krzysztof, additional, Talerczyk, Małgorzata, additional, Berrocal Jaime, Alfonso, additional, Pérez Segura, Pedro, additional, Braña García, Irene, additional, Basté Rotllan, Neus, additional, Mesía Nin, Ricard, additional, Taberna Sanz, Miren, additional, Iglesias Docampo, Lara, additional, Soria Rivas, Ainara, additional, Rueda Domínguez, Antonio, additional, Trigo Pérez, José Manuel, additional, Hong, Ruey-Long, additional, Li, Shau-Hsuan, additional, Wang, Hung-Ming, additional, Yen, Chia-Jui, additional, Yang, Muh-Hwa, additional, Chang, Yi-Fang, additional, Liu, Yi-Chun, additional, Lin, Jin-Ching, additional, Ekenel, Meltem, additional, Harputluoğlu, Hakan, additional, Özyilkan, Özgür, additional, Bılıcı, Ahmet, additional, Şendur, Mehmet Alı Nahıt, additional, Arslan, Cagatay, additional, Harrington, Kevin, additional, Ramkumar, Shanmugasundaram, additional, Gujral, Dorothy, additional, Stewart, Simon, additional, Powell, Melanie, additional, Sibtain, Amen, additional, Roques, Tom, additional, Yip, Kent, additional, Mirza, Arafat, additional, Sivaramalingam, Muthiah, additional, Belman, Neil D, additional, Agarwala, Sanjiv, additional, Anderson, Ian, additional, Patel, Arpan, additional, Maggiore, Ronald, additional, Baumgart, Megan, additional, Fidler, Mary Jo, additional, Kaur, Varinder, additional, Gaughan, Elizabeth, additional, Worden, Francis, additional, Rodriguez, Cristina P, additional, Sukari, Ammar, additional, Wong, Deborah, additional, Yom, Sue, additional, Walsh, William V, additional, Fiorillo, Joseph A, additional, Yorio, Jeffrey T, additional, and Obara, Grzegorz S, additional

Published
2024
Full Text
View/download PDF

28. Patterns of Care, Tolerability, and Safety of the First Cohort of Patients Treated on a Novel High-Field MR-Linac Within the MOMENTUM Study: Initial Results From a Prospective Multi-Institutional Registry

Author

de Mol van Otterloo, Sophie R., Christodouleas, John P., Blezer, Erwin L.A., Akhiat, Hafid, Brown, Kevin, Choudhury, Ananya, Eggert, Dave, Erickson, Beth A., Daamen, Lois A., Faivre-Finn, Corinne, Fuller, Clifton D., Goldwein, Joel, Hafeez, Shaista, Hall, Emma, Harrington, Kevin J., van der Heide, Uulke A., Huddart, Robert A., Intven, Martijn P.W., Kirby, Anna M., Lalondrelle, Susan, McCann, Claire, Minsky, Bruce D., Mook, Stella, Nowee, Marlies E., Oelfke, Uwe, Orrling, Kristina, Philippens, Marielle E.P., Sahgal, Arjun, Schultz, Christopher J., Tersteeg, Robbert J.H.A., Tijssen, Rob H.N., Tree, Alison C., van Triest, Baukelien, Tseng, Chia-Lin, Hall, William A., and Verkooijen, Helena M.

Published
2021
Full Text
View/download PDF

29. Table 1 from Developing and Validating a Multivariable Prognostic-Predictive Classifier for Treatment Escalation of Oropharyngeal Squamous Cell Carcinoma: The PREDICTR-OPC Study

Author

Mehanna, Hisham, primary, Rapozo, Davy, primary, von Zeidler, Sandra V., primary, Harrington, Kevin J., primary, Winter, Stuart C., primary, Hartley, Andrew, primary, Nankivell, Paul, primary, Schache, Andrew G., primary, Sloan, Philip, primary, Odell, Edward W., primary, Thavaraj, Selvam, primary, Hunter, Keith D., primary, Shah, Ketan A., primary, Thomas, Gareth J., primary, Long, Anna, primary, Amel-Kashipaz, Rasoul, primary, Brown, Rachel M., primary, Conn, Brendan, primary, Hall, Gillian L., primary, Matthews, Paul, primary, Weir, Justin, primary, Yeo, Yen, primary, Pring, Miranda, primary, West, Catharine M.L., primary, McCaul, James, primary, Golusinski, Pawel, primary, Sitch, Alice, primary, Spruce, Rachel, primary, Batis, Nikolaos, primary, Bryant, Jennifer L., primary, Brooks, Jill M., primary, Jones, Terence M., primary, Buffa, Francesca, primary, Haider, Syed, primary, and Robinson, Max, primary

Published
2024
Full Text
View/download PDF

30. Data from Developing and Validating a Multivariable Prognostic-Predictive Classifier for Treatment Escalation of Oropharyngeal Squamous Cell Carcinoma: The PREDICTR-OPC Study

Author

Mehanna, Hisham, primary, Rapozo, Davy, primary, von Zeidler, Sandra V., primary, Harrington, Kevin J., primary, Winter, Stuart C., primary, Hartley, Andrew, primary, Nankivell, Paul, primary, Schache, Andrew G., primary, Sloan, Philip, primary, Odell, Edward W., primary, Thavaraj, Selvam, primary, Hunter, Keith D., primary, Shah, Ketan A., primary, Thomas, Gareth J., primary, Long, Anna, primary, Amel-Kashipaz, Rasoul, primary, Brown, Rachel M., primary, Conn, Brendan, primary, Hall, Gillian L., primary, Matthews, Paul, primary, Weir, Justin, primary, Yeo, Yen, primary, Pring, Miranda, primary, West, Catharine M.L., primary, McCaul, James, primary, Golusinski, Pawel, primary, Sitch, Alice, primary, Spruce, Rachel, primary, Batis, Nikolaos, primary, Bryant, Jennifer L., primary, Brooks, Jill M., primary, Jones, Terence M., primary, Buffa, Francesca, primary, Haider, Syed, primary, and Robinson, Max, primary

Published
2024
Full Text
View/download PDF

31. Figure 3 from Developing and Validating a Multivariable Prognostic-Predictive Classifier for Treatment Escalation of Oropharyngeal Squamous Cell Carcinoma: The PREDICTR-OPC Study

Author

Mehanna, Hisham, primary, Rapozo, Davy, primary, von Zeidler, Sandra V., primary, Harrington, Kevin J., primary, Winter, Stuart C., primary, Hartley, Andrew, primary, Nankivell, Paul, primary, Schache, Andrew G., primary, Sloan, Philip, primary, Odell, Edward W., primary, Thavaraj, Selvam, primary, Hunter, Keith D., primary, Shah, Ketan A., primary, Thomas, Gareth J., primary, Long, Anna, primary, Amel-Kashipaz, Rasoul, primary, Brown, Rachel M., primary, Conn, Brendan, primary, Hall, Gillian L., primary, Matthews, Paul, primary, Weir, Justin, primary, Yeo, Yen, primary, Pring, Miranda, primary, West, Catharine M.L., primary, McCaul, James, primary, Golusinski, Pawel, primary, Sitch, Alice, primary, Spruce, Rachel, primary, Batis, Nikolaos, primary, Bryant, Jennifer L., primary, Brooks, Jill M., primary, Jones, Terence M., primary, Buffa, Francesca, primary, Haider, Syed, primary, and Robinson, Max, primary

Published
2024
Full Text
View/download PDF

32. Figure 1 from Developing and Validating a Multivariable Prognostic-Predictive Classifier for Treatment Escalation of Oropharyngeal Squamous Cell Carcinoma: The PREDICTR-OPC Study

Author

Mehanna, Hisham, primary, Rapozo, Davy, primary, von Zeidler, Sandra V., primary, Harrington, Kevin J., primary, Winter, Stuart C., primary, Hartley, Andrew, primary, Nankivell, Paul, primary, Schache, Andrew G., primary, Sloan, Philip, primary, Odell, Edward W., primary, Thavaraj, Selvam, primary, Hunter, Keith D., primary, Shah, Ketan A., primary, Thomas, Gareth J., primary, Long, Anna, primary, Amel-Kashipaz, Rasoul, primary, Brown, Rachel M., primary, Conn, Brendan, primary, Hall, Gillian L., primary, Matthews, Paul, primary, Weir, Justin, primary, Yeo, Yen, primary, Pring, Miranda, primary, West, Catharine M.L., primary, McCaul, James, primary, Golusinski, Pawel, primary, Sitch, Alice, primary, Spruce, Rachel, primary, Batis, Nikolaos, primary, Bryant, Jennifer L., primary, Brooks, Jill M., primary, Jones, Terence M., primary, Buffa, Francesca, primary, Haider, Syed, primary, and Robinson, Max, primary

Published
2024
Full Text
View/download PDF

33. Figure 4 from Developing and Validating a Multivariable Prognostic-Predictive Classifier for Treatment Escalation of Oropharyngeal Squamous Cell Carcinoma: The PREDICTR-OPC Study

Author

Mehanna, Hisham, primary, Rapozo, Davy, primary, von Zeidler, Sandra V., primary, Harrington, Kevin J., primary, Winter, Stuart C., primary, Hartley, Andrew, primary, Nankivell, Paul, primary, Schache, Andrew G., primary, Sloan, Philip, primary, Odell, Edward W., primary, Thavaraj, Selvam, primary, Hunter, Keith D., primary, Shah, Ketan A., primary, Thomas, Gareth J., primary, Long, Anna, primary, Amel-Kashipaz, Rasoul, primary, Brown, Rachel M., primary, Conn, Brendan, primary, Hall, Gillian L., primary, Matthews, Paul, primary, Weir, Justin, primary, Yeo, Yen, primary, Pring, Miranda, primary, West, Catharine M.L., primary, McCaul, James, primary, Golusinski, Pawel, primary, Sitch, Alice, primary, Spruce, Rachel, primary, Batis, Nikolaos, primary, Bryant, Jennifer L., primary, Brooks, Jill M., primary, Jones, Terence M., primary, Buffa, Francesca, primary, Haider, Syed, primary, and Robinson, Max, primary

Published
2024
Full Text
View/download PDF

34. Table 2 from Developing and Validating a Multivariable Prognostic-Predictive Classifier for Treatment Escalation of Oropharyngeal Squamous Cell Carcinoma: The PREDICTR-OPC Study

Author

Mehanna, Hisham, primary, Rapozo, Davy, primary, von Zeidler, Sandra V., primary, Harrington, Kevin J., primary, Winter, Stuart C., primary, Hartley, Andrew, primary, Nankivell, Paul, primary, Schache, Andrew G., primary, Sloan, Philip, primary, Odell, Edward W., primary, Thavaraj, Selvam, primary, Hunter, Keith D., primary, Shah, Ketan A., primary, Thomas, Gareth J., primary, Long, Anna, primary, Amel-Kashipaz, Rasoul, primary, Brown, Rachel M., primary, Conn, Brendan, primary, Hall, Gillian L., primary, Matthews, Paul, primary, Weir, Justin, primary, Yeo, Yen, primary, Pring, Miranda, primary, West, Catharine M.L., primary, McCaul, James, primary, Golusinski, Pawel, primary, Sitch, Alice, primary, Spruce, Rachel, primary, Batis, Nikolaos, primary, Bryant, Jennifer L., primary, Brooks, Jill M., primary, Jones, Terence M., primary, Buffa, Francesca, primary, Haider, Syed, primary, and Robinson, Max, primary

Published
2024
Full Text
View/download PDF

35. Figure 2 from Developing and Validating a Multivariable Prognostic-Predictive Classifier for Treatment Escalation of Oropharyngeal Squamous Cell Carcinoma: The PREDICTR-OPC Study

Author

Mehanna, Hisham, primary, Rapozo, Davy, primary, von Zeidler, Sandra V., primary, Harrington, Kevin J., primary, Winter, Stuart C., primary, Hartley, Andrew, primary, Nankivell, Paul, primary, Schache, Andrew G., primary, Sloan, Philip, primary, Odell, Edward W., primary, Thavaraj, Selvam, primary, Hunter, Keith D., primary, Shah, Ketan A., primary, Thomas, Gareth J., primary, Long, Anna, primary, Amel-Kashipaz, Rasoul, primary, Brown, Rachel M., primary, Conn, Brendan, primary, Hall, Gillian L., primary, Matthews, Paul, primary, Weir, Justin, primary, Yeo, Yen, primary, Pring, Miranda, primary, West, Catharine M.L., primary, McCaul, James, primary, Golusinski, Pawel, primary, Sitch, Alice, primary, Spruce, Rachel, primary, Batis, Nikolaos, primary, Bryant, Jennifer L., primary, Brooks, Jill M., primary, Jones, Terence M., primary, Buffa, Francesca, primary, Haider, Syed, primary, and Robinson, Max, primary

Published
2024
Full Text
View/download PDF

36. Supplementary Data 1 from Developing and Validating a Multivariable Prognostic-Predictive Classifier for Treatment Escalation of Oropharyngeal Squamous Cell Carcinoma: The PREDICTR-OPC Study

Author

Mehanna, Hisham, primary, Rapozo, Davy, primary, von Zeidler, Sandra V., primary, Harrington, Kevin J., primary, Winter, Stuart C., primary, Hartley, Andrew, primary, Nankivell, Paul, primary, Schache, Andrew G., primary, Sloan, Philip, primary, Odell, Edward W., primary, Thavaraj, Selvam, primary, Hunter, Keith D., primary, Shah, Ketan A., primary, Thomas, Gareth J., primary, Long, Anna, primary, Amel-Kashipaz, Rasoul, primary, Brown, Rachel M., primary, Conn, Brendan, primary, Hall, Gillian L., primary, Matthews, Paul, primary, Weir, Justin, primary, Yeo, Yen, primary, Pring, Miranda, primary, West, Catharine M.L., primary, McCaul, James, primary, Golusinski, Pawel, primary, Sitch, Alice, primary, Spruce, Rachel, primary, Batis, Nikolaos, primary, Bryant, Jennifer L., primary, Brooks, Jill M., primary, Jones, Terence M., primary, Buffa, Francesca, primary, Haider, Syed, primary, and Robinson, Max, primary

Published
2024
Full Text
View/download PDF

37. T-cell receptor determinants of response to chemoradiation in locally-advanced HPV16-driven malignancies

Author

Nenclares, Pablo, primary, Larkeryd, Adrian, additional, Manodoro, Floriana, additional, Lee, Jen Y., additional, Lalondrelle, Susan, additional, Gilbert, Duncan C., additional, Punta, Marco, additional, O’Leary, Ben, additional, Rullan, Antonio, additional, Sadanandam, Anguraj, additional, Chain, Benny, additional, Melcher, Alan, additional, Harrington, Kevin J., additional, and Bhide, Shreerang A., additional

Published
2024
Full Text
View/download PDF

38. International Recommendations on Reirradiation by Intensity Modulated Radiation Therapy for Locally Recurrent Nasopharyngeal Carcinoma

Author

Ng, Wai Tong, Soong, Yoke Lim, Ahn, Yong Chan, AlHussain, Hussain, Choi, Horace C.W., Corry, June, Grégoire, Vincent, Harrington, Kevin J., Hu, Chao Su, Jensen, Kenneth, Kwong, Dora L., Langendijk, Johannes A., Le, Quynh Thu, Lee, Nancy Y., Lin, Jin Ching, Lu, Tai Xiang, Mendenhall, William M., O’Sullivan, Brian, Ozyar, Enis, Pan, Jian Ji, Peters, Lester J., Poh, Sharon S., Rosenthal, David I., Sanguineti, Giuseppe, Tao, Yungan, Wee, Joseph T., Yom, Sue S., Chua, Melvin L.K., and Lee, Anne W.M.

Published
2021
Full Text
View/download PDF

39. Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma

Author

Haas, Lisa, Elewaut, Anais, Gerard, Camille L., Umkehrer, Christian, Leiendecker, Lukas, Pedersen, Malin, Krecioch, Izabela, Hoffmann, David, Novatchkova, Maria, Kuttke, Mario, Neumann, Tobias, da Silva, Ines Pires, Witthock, Harriet, Cuendet, Michel A., Carotta, Sebastian, Harrington, Kevin J., Zuber, Johannes, Scolyer, Richard A., Long, Georgina V., Wilmott, James S., Michielin, Olivier, Vanharanta, Sakari, Wiesner, Thomas, and Obenauf, Anna C.

Published
2021
Full Text
View/download PDF

40. Predictive Modelling of Toxicity Resulting from Radiotherapy Treatments of Head and Neck Cancer

Author

Dean, Jamie A., Welsh, Liam C., Harrington, Kevin J., Nutting, Christopher M., and Gulliford, Sarah L.

Subjects
Physics - Medical Physics, Computer Science - Computational Engineering, Finance, and Science, Quantitative Biology - Quantitative Methods
Abstract

In radiotherapy for head and neck cancer, the radiation dose delivered to the pharyngeal mucosa (mucosal lining of the throat) is thought to be a major contributing factor to dysphagia (swallowing dysfunction), the most commonly reported severe toxicity. There is a variation in the severity of dysphagia experienced by patients. Understanding the role of the dose distribution in dysphagia would allow improvements in the radiotherapy technique to be explored. The 3D dose distributions delivered to the pharyngeal mucosa of 249 patients treated as part of clinical trials were reconstructed. Pydicom was used to extract DICOM (digital imaging and communications in medicine) data (the standard file formats for medical imaging and radiotherapy data). NumPy and SciPy were used to manipulate the data to generate 3D maps of the dose distribution delivered to the pharyngeal mucosa and calculate metrics describing the dose distribution. Multivariate predictive modelling of severe dysphagia, including descriptions of the dose distribution and relevant clinical factors, was performed using Pandas and SciKit-Learn. Matplotlib and Mayavi were used for 2D and 3D data visualisation. A support vector classification model, with feature selection using randomised logistic regression, to predict radiation-induced severe dysphagia, was trained. When this model was independently validated, the area under the receiver operating characteristic curve was 0.54. The model has poor predictive power and work is ongoing to improve the model through alternative feature engineering and statistical modelling approaches., Comment: Part of the Proceedings of the 7th European Conference on Python in Science (EuroSciPy 2014), Pierre de Buyl and Nelle Varoquaux editors, (2014)

Published
2014

41. A comprehensive examination of mental health in patients with head and neck cancer: systematic review and meta-analysis.

Author

Jimenez-Labaig, Pablo, Aymerich, Claudia, Braña, Irene, Rullan, Antonio, Cacicedo, Jon, González-Torres, Miguel Ángel, Harrington, Kevin J, and Catalan, Ana

Subjects
HEAD & neck cancer, MENTAL health
Abstract

Background Patients with head and neck cancer present particularly considerable levels of emotional distress. However, the actual rates of clinically relevant mental health symptoms and disorders among this population remain unknown. Methods A Preferred Reporting Items for Systematic Review and Meta-Analyses and Meta-analyses of Observational Studies in Epidemiology–compliant systematic review and quantitative random-effects meta-analysis was performed to determine suicide incidence and the prevalence of depression, anxiety, distress, posttraumatic stress, and insomnia in this population. MEDLINE, Web of Science, Cochrane Central Register, KCI Korean Journal database, SciELO, Russian Science Citation Index, and Ovid-PsycINFO databases were searched from database inception to August 1, 2023 (PROSPERO: CRD42023441432). Subgroup analyses and meta-regressions were performed to investigate the effect of clinical, therapeutical, and methodological factors. Results A total of 208 studies (n = 654 413; median age = 60.7 years; 25.5% women) were identified. Among the patients, 19.5% reported depressive symptoms (95% confidence interval [CI] = 17% to 21%), 17.8% anxiety symptoms (95% CI = 14% to 21%), 34.3% distress (95% CI = 29% to 39%), 17.7% posttraumatic symptoms (95% CI = 6% to 41%), and 43.8% insomnia symptoms (95% CI = 35% to 52%). Diagnostic criteria assessments revealed lower prevalence of disorders: 10.3% depression (95% CI = 7% to 13%), 5.6% anxiety (95% CI = 2% to 10%), 9.6% insomnia (95% CI = 1% to 40%), and 1% posttraumatic stress (95% CI = 0% to 84.5%). Suicide pooled incidence was 161.16 per 100 000 individuals per year (95% CI = 82 to 239). Meta-regressions found a statistically significant higher prevalence of anxiety in patients undergoing primary chemoradiation compared with surgery and increased distress in smokers and advanced tumor staging. European samples exhibited lower prevalence of distress. Conclusions Patients with head and neck cancer presented notable prevalence of mental health concerns in all domains. Suicide remains a highly relevant concern. The prevalence of criteria-meeting disorders is significantly lower than clinically relevant symptoms. Investigating the effectiveness of targeted assessments for disorders in highly symptomatic patients is essential. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

43. Developing and Validating a Multivariable Prognostic-Predictive Classifier for Treatment Escalation of Oropharyngeal Squamous Cell Carcinoma: The PREDICTR-OPC Study

Author

Mehanna, Hisham, primary, Rapozo, Davy, additional, von Zeidler, Sandra V., additional, Harrington, Kevin J., additional, Winter, Stuart C., additional, Hartley, Andrew, additional, Nankivell, Paul, additional, Schache, Andrew G., additional, Sloan, Philip, additional, Odell, Edward W., additional, Thavaraj, Selvam, additional, Hunter, Keith D., additional, Shah, Ketan A., additional, Thomas, Gareth J., additional, Long, Anna, additional, Amel-Kashipaz, Rasoul, additional, Brown, Rachel M., additional, Conn, Brendan, additional, Hall, Gillian L., additional, Matthews, Paul, additional, Weir, Justin, additional, Yeo, Yen, additional, Pring, Miranda, additional, West, Catharine M.L., additional, McCaul, James, additional, Golusinski, Pawel, additional, Sitch, Alice, additional, Spruce, Rachel, additional, Batis, Nikolaos, additional, Bryant, Jennifer L., additional, Brooks, Jill M., additional, Jones, Terence M., additional, Buffa, Francesca, additional, Haider, Syed, additional, and Robinson, Max, additional

Published
2023
Full Text
View/download PDF

47. Sculpting the tumour microenvironment by combining radiotherapy and ATR inhibition for curative-intent anti-PD-L1- and anti-NKG2A-based adjuvant immunotherapy

Author

Patin, Emmanuel Christian, primary, Nenclares, Pablo, additional, Chan Wah Hak, Charleen, additional, Dillon, Magnus T, additional, Patrikeev, Anton, additional, McLaughlin, Martin, additional, Grove, Lorna, additional, Foo, Shane, additional, Soliman, Heba, additional, Barata, Joao P, additional, Marsden, Joanna, additional, Baldock, Holly, additional, Roulstone, Victoria, additional, Kyula, Joan, additional, Burley, Amy, additional, Hubbard, Lisa C, additional, Pedersen, Malin, additional, Smith, Simon A, additional, Clancy-thompson, Eleanor, additional, Melcher, Alan A, additional, Ono, Masahiro, additional, Rullan, Antonio, additional, and Harrington, Kevin J, additional

Published
2023
Full Text
View/download PDF

50. International Guideline on Dose Prioritization and Acceptance Criteria in Radiation Therapy Planning for Nasopharyngeal Carcinoma

Author

Lee, Anne W., Ng, Wai Tong, Pan, Jian Ji, Chiang, Chi-Leung, Poh, Sharon S., Choi, Horace C., Ahn, Yong Chan, AlHussain, Hussain, Corry, June, Grau, Cai, Grégoire, Vincent, Harrington, Kevin J., Hu, Chao Su, Kwong, Dora L., Langendijk, Johannes A., Le, Quynh Thu, Lee, Nancy Y., Lin, Jin Ching, Lu, Tai Xiang, Mendenhall, William M., O'Sullivan, Brian, Ozyar, Enis, Peters, Lester J., Rosenthal, David I., Sanguineti, Giuseppe, Soong, Yoke Lim, Tao, Yungan, Yom, Sue S., and Wee, Joseph T.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results